Richter Gedeon Nyrt (RICHTER):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Richter Gedeon Nyrt (RICHTER) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9892
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:47
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ハンガリー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Richter Gedeon Nyrt (Richter) is a pharmaceutical company that develops, manufactures and commercializes a wide range of drugs including original, generic and licensed products and over-the-counter (OTC) medicines. The company’s product portfolio encompasses medicines to treat gynaecological diseases, cardiovascular diseases, gastrointestinal diseases and central nervous system disorders. Richter’s research activities focus exclusively on the development of original small molecules, recombinant biotechnology and generic product development. It operates sales network in Hungary, Central Eastern Europe and the Commonwealth of Independent States (CIS) countries. The company has a research and development unit in Central Eastern Europe. Richter is headquartered in Budapest, Hungary.

Richter Gedeon Nyrt (RICHTER) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Richter Gedeon Nyrt, Medical Devices Deals, 2012 to YTD 2018 11
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deal Details 14
Asset Purchase 14
Gedeon Richter Acquires Bemfola US Rights from Fertility Biotech 14
Gedeon Richter Acquires Esmya from Laboratoire HRA Pharma 15
Venture Financing 16
Finox Biotech Raises US$24.4 Million In Venture Financing 16
Partnerships 17
Evestra Enters into Agreement with Gedeon Richter 17
Gedeon Richter Enters into Distribution Agreement with Allergan 18
BMV Medica Enters into Marketing Agreement with Gedeon Richter Mexico 19
Evestra Enters Into R&D Agreement With Gedeon Richter For Contraceptive Products 20
Orion Enters Into R&D Agreement With Gedeon Richter For Cognitive Disorders 21
Gedeon Richter Forms Joint Venture With Rxmidas Pharma 22
Licensing Agreements 23
Gedeon Richter Enters into Licensing Agreement with Collins 23
Richter Gedeon Enters into Licensing Agreement with Mithra Pharma 24
Richter Gedeon Enters into Licensing Agreement with Pharmanest 25
Richter Gedeon Enters into Licensing Agreement with DM Bio 26
Recordati Enters into Licensing Agreement with Gedeon Richter for Cariprazine 27
Mithra Pharmaceuticals Enters into Licensing Agreement with Gedeon Richter 28
Gedeon Richter Enters into Licensing Agreement with Bayer HealthCare 29
Gedeon Richter Enters Into Licensing Agreement With Acrux For Estradiol Skin Spray 30
STADA Arzneimittel Enters into Licensing Agreement with Gedeon Richter 31
Gedeon Richter Expands Licensing Agreement With HRA Pharma For Esmya 32
Equity Offering 33
Gedeon Richter Romania Plans to Raise USD2.5 Million in Private Placement of Shares 33
Finox Biotech Raises USD21.4 Million in Private Placement of Shares 34
Acquisition 35
Gedeon Richter Acquires Finox for USD193.8 Million 35
Gedeon Richter Acquires Remaining 50% Joint Venture Stake in Gedeon Richter Rxmidas from Rxmidas Pharma 36
Gedeon Richter Acquires Majority Stake in Mediplus 37
Richter Gedeon Acquires 70% Stake In DNA Pharma 38
Richter Acquires 51% Stake In Next Pharma 39
Richter Gedeon Nyrt – Key Competitors 40
Richter Gedeon Nyrt – Key Employees 41
Richter Gedeon Nyrt – Locations And Subsidiaries 42
Head Office 42
Other Locations & Subsidiaries 42
Joint Venture 44
Recent Developments 45
Product News 45
05/18/2017: Gedeon Richter Receives CHMP Positive Opinion for Reagila (cariprazine) 45
Product Approvals 46
Mar 08, 2017: FDA Accepts Supplemental New Drug Application For VRAYLAR (cariprazine) 46
Appendix 47
Methodology 47
About GlobalData 47
Contact Us 47
Disclaimer 47

List of Tables
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Richter Gedeon Nyrt, Deals By Therapy Area, 2012 to YTD 2018 9
Richter Gedeon Nyrt, Medical Devices Deals, 2012 to YTD 2018 11
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Gedeon Richter Acquires Bemfola US Rights from Fertility Biotech 14
Gedeon Richter Acquires Esmya from Laboratoire HRA Pharma 15
Finox Biotech Raises US$24.4 Million In Venture Financing 16
Evestra Enters into Agreement with Gedeon Richter 17
Gedeon Richter Enters into Distribution Agreement with Allergan 18
BMV Medica Enters into Marketing Agreement with Gedeon Richter Mexico 19
Evestra Enters Into R&D Agreement With Gedeon Richter For Contraceptive Products 20
Orion Enters Into R&D Agreement With Gedeon Richter For Cognitive Disorders 21
Gedeon Richter Forms Joint Venture With Rxmidas Pharma 22
Gedeon Richter Enters into Licensing Agreement with Collins 23
Richter Gedeon Enters into Licensing Agreement with Mithra Pharma 24
Richter Gedeon Enters into Licensing Agreement with Pharmanest 25
Richter Gedeon Enters into Licensing Agreement with DM Bio 26
Recordati Enters into Licensing Agreement with Gedeon Richter for Cariprazine 27
Mithra Pharmaceuticals Enters into Licensing Agreement with Gedeon Richter 28
Gedeon Richter Enters into Licensing Agreement with Bayer HealthCare 29
Gedeon Richter Enters Into Licensing Agreement With Acrux For Estradiol Skin Spray 30
STADA Arzneimittel Enters into Licensing Agreement with Gedeon Richter 31
Gedeon Richter Expands Licensing Agreement With HRA Pharma For Esmya 32
Gedeon Richter Romania Plans to Raise USD2.5 Million in Private Placement of Shares 33
Finox Biotech Raises USD21.4 Million in Private Placement of Shares 34
Gedeon Richter Acquires Finox for USD193.8 Million 35
Gedeon Richter Acquires Remaining 50% Joint Venture Stake in Gedeon Richter Rxmidas from Rxmidas Pharma 36
Gedeon Richter Acquires Majority Stake in Mediplus 37
Richter Gedeon Acquires 70% Stake In DNA Pharma 38
Richter Acquires 51% Stake In Next Pharma 39
Richter Gedeon Nyrt, Key Competitors 40
Richter Gedeon Nyrt, Key Employees 41
Richter Gedeon Nyrt, Other Locations 42
Richter Gedeon Nyrt, Subsidiaries 42
Richter Gedeon Nyrt, Joint Venture 44

List of Figures
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Richter Gedeon Nyrt, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Richter Gedeon Nyrt, Medical Devices Deals, 2012 to YTD 2018 11

★海外企業調査レポート[Richter Gedeon Nyrt (RICHTER):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Grupa Azoty Zaklady Chemiczne Police SA (PCE):企業の財務・戦略的SWOT分析
    Grupa Azoty Zaklady Chemiczne Police SA (PCE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Chori Co Ltd (8014):企業の財務・戦略的SWOT分析
    Chori Co Ltd (8014) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Juhl Energy Inc:企業の戦略的SWOT分析
    Juhl Energy Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Globe Telecom Inc (GLO):企業の財務・戦略的SWOT分析
    Globe Telecom Inc (GLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Bank of the Ryukyus, Ltd.:企業の戦略・SWOT・財務情報
    Bank of the Ryukyus, Ltd. - Strategy, SWOT and Corporate Finance Report Summary Bank of the Ryukyus, Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Pear Therapeutics Inc:企業の製品パイプライン分析2018
    Summary Pear Therapeutics Inc (Pear Therapeutics) develops software-based prescription digital therapeutics for the treatment of severe medical conditions and diseases. Its product pipeline includes reSET-O for treating opioid use disorder (OUD) in conjunction with opioid replacement therapy; Thrive …
  • Holding Slovenske elektrarne doo:企業の戦略的SWOT分析
    Holding Slovenske elektrarne doo - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major pr …
  • Teledyne Technologies Inc (TDY):企業の財務・戦略的SWOT分析
    Teledyne Technologies Inc (TDY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Banco Popular Dominicano S.A.:企業の戦略・SWOT・財務情報
    Banco Popular Dominicano S.A. - Strategy, SWOT and Corporate Finance Report Summary Banco Popular Dominicano S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • Ario Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Ario Pharma Ltd (Ario) is a drug development company that develops new therapeutics for the treatment of pain. The company develops small molecule TRPA1 antagonists to treat neuropathic and inflammatory pain. Its TRPA1 activators include pungent or noxious compounds such as allyl isothiocyan …
  • Big River Gold Ltd (CAS):企業の財務・戦略的SWOT分析
    Summary Big River Gold Ltd (Big River Gold) is formerly known as Crusader resources Ltd is a mineral exploration company. The company explores for gold, iron ore and tin deposits. Its projects portfolio includes Borborema Gold project, Posse Iron Ore project, Tarantula Tungsten project, Juruena Gold …
  • XL-protein GmbH:製薬・医療:M&Aディール及び事業提携情報
    Summary XL-protein GmbH (XL-protein) is a biopharmaceutical company that develops second generation biopharmaceutical drugs. The company develops PASylation technology, designed to enable the biopharmaceuticals drug development with extended plasma half-life and enhanced action. It provides its tech …
  • Wolverine World Wide, Inc.:企業の戦略・SWOT・財務情報
    Wolverine World Wide, Inc. - Strategy, SWOT and Corporate Finance Report Summary Wolverine World Wide, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Telia Company AB:企業の戦略・SWOT・財務情報
    Telia Company AB - Strategy, SWOT and Corporate Finance Report Summary Telia Company AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Cancer Genetics Inc (CGIX):企業の財務・戦略的SWOT分析
    Summary Cancer Genetics Inc (CGI) is a pharmaceutical company that offers diagnostic products and services enabling precision medicine in the field of oncology. It offers products such as CGH microarrays, next-generation sequencing and DNA-FISH Probes. The company's oncology tests and laboratory ser …
  • Pharmathen Global BV:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmathen Global BV (Pharmathen) is a pharmaceutical company with focus on the research and development of generics, active pharmaceutical ingredients (APIs), and finished formulations. Its vast product portfolio includes antibiotics, antimycotics, antivirals, antidiabetics and topical pain …
  • CAT Telecom Public Co Ltd:企業の戦略的SWOT分析
    CAT Telecom Public Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Black Hills Corporation (BKH)-石油・ガス分野:企業M&A・提携分析
    Summary Black Hills Corporation (BHC) is a vertically-integrated energy company which offers electricity and natural gas. The company produces, transmits, and distributes electricity; and sells natural gas on retail and wholesale basis. It generates electricity from natural gas, coal, diesel oil, an …
  • CVRx Inc-医療機器分野:企業M&A・提携分析
    Summary CVRx Inc (CVRx) is a medical device company that develops and designs implantable device. The company offers barostim neo system, which is designed to trigger the body’s natural blood flow regulation system to treat high blood pressure and heart failure. Its products are used in the treatmen …
  • Sinovac Biotech Ltd (SVA):製薬・医療:M&Aディール及び事業提携情報
    Summary Sinovac Biotech Ltd (Sinovac Biotech) is a biopharmaceutical company that develops, manufactures and commercializes vaccines. The company’s products comprise healive, bilive, anflu, panflu and panflu, among others. Its healive is an inactivated hepatitis A vaccine. Sinovac Biotech’s bilive i …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆